Germline BRCA mutations and other HR genes may offer biomarkers for response to this treatment.
The statement emphasizes strategies for multidisciplinary care, and proposes an algorithm for clinical management of bone metastasis in RCC.
PFS, tumor response, and safety outcomes were similar in patient cohorts under age 75 vs those 75 years of age and older.
Oncology nurse leaders share insights into the care of vulnerable oncology populations—from ED triage to tailored telehealth sessions for homeless populations.
Next-generation sequencing may prove to be a useful tool in the identification of co-mutations associated with resistance, an MD Anderson study suggests.
A pilot protocol developed at Memorial Sloan Kettering Cancer Center resulted in exponential increases in both influenza and pneumococcal vaccinations in the outpatient setting.
Overexpression of IKZF1 facilitates immune attack on skin cancer and other solid tumors.
A team from Children’s Healthcare of Atlanta reports unexpected factors determining which adolescents participated in sperm banking.
Three and 6 months after undergoing the psychotherapeutic intervention Managing Cancer and Living Meaningfully (CALM), participants reported less-severe depressive symptoms.
More than 20% of patients with non–clear cell RCC had a germline mutation, and half of this group could benefit from direct systemic therapy.
Quit rates reported by a smoking-cessation program at Duke Cancer Center increased from 17% to 34% in the 2 years since it was implemented.
A small study has found that men with cancer were less likely than women to prefer palliative care if informed that continued treatment would not be helpful.
While over half of survivors had heard of metabolic syndrome, in one-third with the condition, fewer than 10% had been diagnosed; educational strategies may be of benefit.
The OS benefit associated with standard treatment diminished in patients older than 80 with high comorbidity scores, but other age groups fared better.
There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting.